Evidence map›Paper›PMID 34513051›Full record

ArticleSovremennye tekhnologii v meditsine2020

Autologous and Pooled Tumor Lysates in Combined Immunotherapy of Patients with Glioblastoma.

S V Mishinov, A Ya Budnik, V V Stupak, O Yu Leplina, T V Tyrinova, A A Ostanin, E R Chernykh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

S V MishinovSenior Researcher, Novosibirsk Scientific Research Institute of Traumatology and Orthopedics named after Ya.L. Tsivyan of the Ministry of Health of the Russian Federation, 17 Frunze St., Novosibirsk, 630091, Russia.
A Ya BudnikResident, Novosibirsk Scientific Research Institute of Traumatology and Orthopedics named after Ya.L. Tsivyan of the Ministry of Health of the Russian Federation, 17 Frunze St., Novosibirsk, 630091, Russia.
V V StupakProfessor, Head of Neurosurgery Research Department, Novosibirsk Scientific Research Institute of Traumatology and Orthopedics named after Ya.L. Tsivyan of the Ministry of Health of the Russian Federation, 17 Frunze St., Novosibirsk, 630091, Russia.
O Yu LeplinaLeading Researcher, Laboratory of Cellular Immunotherapy, Scientific Research Institute of Fundamental and Clinical Immunology, 14 Yadrintsevskaya St., Novosibirsk, 630099, Russia.
T V TyrinovaResearcher, Laboratory of Cellular Immunotherapy, Scientific Research Institute of Fundamental and Clinical Immunology, 14 Yadrintsevskaya St., Novosibirsk, 630099, Russia.
A A OstaninProfessor, Chief Researcher, Laboratory of Cellular Immunotherapy, Scientific Research Institute of Fundamental and Clinical Immunology, 14 Yadrintsevskaya St., Novosibirsk, 630099, Russia.
E R ChernykhProfessor, Corresponding Member of the Russian Academy of Sciences, Head of the Laboratory of Cellular Immunotherapy, Scientific Research Institute of Fundamental and Clinical Immunology, 14 Yadrintsevskaya St., Novosibirsk, 630099, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although major progress has been made in the standard treatment for glioblastomas, encompassing the maximal surgical resection, chemotherapy and radiation therapy, it is possible to increase survival rates significantly only in a few patients. Therefore, it is necessary to explore new therapeutic modalities, one of which is immunotherapy. MATERIALS AND

methodsAll patients (n=58, including 30 males and 28 females aged 18-70 years) were randomized into three groups, two of which received immunotherapy based on injection of autologous dendritic cells pulsed with autologous tumor lysates (first protocol) or pooled lysates (second protocol) from more than one tumor, in addition to the planned standard treatment. The patients of group 3 (control) received the standard comprehensive treatment encompassing the maximum safe tumor resection followed by radiation therapy and chemotherapy.

resultsThe tolerability of both applied immunotherapy protocols was good: there were no anaphylactic reactions observed or patients who prematurely discontinued participation in the study. The final analysis of the data revealed no significant differences in median survival values of patients in each of the three groups. However, when analyzing the Karnofsky Performance Status in patients of group 2, it was found that it tended to improve.

conclusionThe study shows that the proposed immunotherapy protocols are safe for clinical use and have the potential to improve the patient's life quality. However, these findings should be considered intermediate until the findings of multicenter randomized clinical trials with a larger number of patients are obtained.

Indexed as

autologous tumor lysatedendritic cellsglioblastomaimmunotherapyoverall survival of glioblastoma patientspooled tumor lysate

Identifiers

PMID34513051
PMCPMC8353674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.